Therapeutic use of a thienylcyclohexylamine derivative
AssigneeSociete de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
InventorsGuy Lallement, Pierre D'Arbigny, Jean-Marc Kamenka
Life of this patent
Estimating the term…
Abstract
A method of inhibiting effects of exogenous neurotoxic or neurotoxinic products in warm-blooded animals comprising administering to warm-blooded animals before exposure to said products an inhibitorily effective amount of reversible cholinesterase inhibitor selected from the group consisting of pyridostigmine and physostigmine followed by administration of an inhibitorily effective amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form.
Claims7
A composition for inhibiting exogenous neurotropic or neurotoxinic compounds comprising an inhibitorily effective amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form and at least one member of the group consisting of an anticonvulsive substance, an anticholinergic substance and a substance which reactivates cholinesterases.
A composition for inhibiting exogenous neurotropic or neurotoxinic effects comprising an inhibitorily effective amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form and at least one anticonvulsive substance, at least one anticholinergic substance and at least one substance which reactivates cholinesterases.
Dependencies are inferred from the claim text.